Medical Hypotheses
Volume 55, Issue 5 , Pages 379-382 , November 2000

Ursodeoxycholic acid to inhibit the growth of hepatic metastases

Received 2 September 1999 ,Accepted 6 January 2000.

References 

    REFERENCES
  1. Yoong KF, Afford SC, Randhawa S, Hubscher SB, Adams DH. Fas/fas ligand interaction in human colorectal hepatic metastases: a mechanism of hepatocyte destruction to facilitate local tumor invasion. Am J Pathol. 1999;154:693–703
  2. Vlahcvic ZR, Heuman DM, Hylemon PB. Physiology and pathophysiology of enterohepatic circulation of bile acids. In:  Zakim D,  Boyer TD editor. Hepatology: A Textbook of Liver Disease, 3rdedn.. Philadelphia: W.B Saunders; 1996;p. 376–417
  3. Okishio T, Nair PB. Studies on bile acids. Some observations on the intracellular localization of major bile acids in rat liver. Biochemistry. 1966;5:3662–3668
  4. Norlander A, Norman A. Bile acid metabolism in non-jaundiced patients with malignant liver tumours. Scand J Gastroenterol. 1982;17:849–853
  5. Stiehl A, Benz C, Sauer P. Mechanism of hepatoprotective action of bile salts in liver disease. Gastroenterol Clin North Am. 1999;28:195–209
  6. Martinez JD, Stratagoules ED, LaRue JM. Different bile acids exhibit distinct biological effects: the tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation. Nutr Cancer. 1998;31:111–118
  7. Faubion WA, Guicciardi ME, Miyoshi H. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J Clin Invest. 1999;103:137–145
  8. Rodrigues CM, Fan G, Ma X, Kren BT, Steer CJ. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest. 1998;101:2790–2799
  9. Samaha HS, Asher E, Payne CM, Bernstein C, Bernstein H. Evaluation of cell death in EBV-transformed lymphocytes using agarose gel electrophoresis, light microscopy and electron microscopy 1. Induction of classic apoptosis by the bile salt, sodium deoxycholate. Leuk Lymph. 1995;19:95–105
  10. Galle PR, Hofmann WJ, Walczak H. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med. 1995;182:1223–1230
  11. Moller P, Koretz K, Leithauser F. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer. 1994;57:371–377
  12. Owen-Schaub LB, Radinsky R, Kruzel E, Berry K, Yonehara S. Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res. 1994;54:1580–1586
  13. Garewal H, Bernstein H, Bernstein C, Sampliner R, Payne C. Reduced bile acid-induced apoptosis in ‘normal’ colorectal mucosa: a potential biological marker for cancer risk. Cancer Res. 1996;56:1480–1483
  14. Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J Clin Invest. 1994;94:954–964
  15. Hiramatsu N, Hayashi N, Katayama K. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology. 1994;19:1354–1359
  16. Leithauser F, Dhein J, Mechtersheimer G. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest. 1993;69:415–429
  17. Miyai K, Javitt NB, Gochman N, Jones HM, Baker D. Hepatotoxicity of bile acids in rabbits: ursodeoxycholic acid is less toxic than chenodeoxycholic acid. Lab Invest. 1982;46:428–437
  18. Gressner AM, Lahme B, Mannherz HG, Polzar B. TGF-beta-mediated hepatocellular apoptosis by rat and human hepatoma cells and primary rat hepatocytes. J Hepatol. 1997;26:1079–1082
  19. Schroy P, Rifkin J, Coffey RJ, Winawer S, Friedman E. Role of transforming growth factor beta 1 in induction of colon carcinoma differentiation by hexamethylene bisacetamide. Cancer Res. 1990;50:261–265
  20. Robson H, Anderson E, James RD, Schofield PF. Transforming growth factor beta 1 expression in human colorectal tumours: an independent prognostic marker in a subgroup of poor prognosis patients. Br J Cancer. 1996;74:753–758
  21. Friedman E, Gold LI, Klimstra D, Zeng ZS, Winawer S, Cohen A. High levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer. Cancer Epidemiol Biomarkers Prev. 1995;4:549–564
  22. Shim KS, Kim KH, Han WS, Park EB. Elevated serum levels of transforming growth factor-beta 1 in patients with colorectal carcinoma: its association with tumor progression and its significant decrease after curative surgical resection. Cancer. 1999;85:554–561
  23. Picon A, Gold LI, Wang J, Cohen A, Friedman E. A subset of metastatic human colon cancers expresses elevated levels of transforming growth factor beta 1. Cancer Epidemiol Biomarkers Prev. 1998;7:497–504
  24. Friess H, Yamanaka Y, Buchler M. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology. 1993;105:1846–1856
  25. Oberhammer FA, Qin HM. Effect of three tumour promoters on the stability of hepatocyte cultures and apoptosis after transforming growth factor-beta 1. Carcinogenesis. 1995;16:1363–1371
  26. Bachrach WH, Hofmann AF. Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. Dig Dis Sci. 1982;27:737–761
  27. Benz C, Angermuller S, Tox U. Effect of tauroursodeoxycholic acid on bile-acid-induced apoptosis and cytolysis in rat hepatocytes. J Hepatol. 1998;28:99–106
  28. Liu J, Liu Y, Habeebu SS, Klaassen CD. Metallothionein (MT)-null mice are sensitive to cisplatin-induced hepatotoxicity. Toxicol Appl Pharmacol. 1998;149:24–31
  29. Leist M, Gantner F, Naumann H. Tumor necrosis factor-induced apoptosis during the poisoning of mice with hepatotoxins. Gastroenterology. 1997;112:923–934
  30. Carthew P, Nolan BM, Edwards RE, Smith LL. The role of cell death and cell proliferation in the promotion of rat liver tumours by tamoxifen. Cancer Lett. 1996;106:163–169
  31. Maccarrone M, Nieuwenhuizen WE, Dullens HF. Membrane modification in human erythroleukemia K562 cells during induction of programmed cell death by transforming growth factor beta 1 or cisplatin. Eur J Biochem. 1996;241:297–302
  32. Hartmann K, Wagelie-Steffen AL, von Stebut E, Metcalfe DD. Fas (CD95, APO-1) antigen expression and function in murine mast cells. J Immunol. 1997;159:4006–4014
  33. Mullauer L, Grasl-Kraupp B, Bursch W, Schulte-Hermann R. Transforming growth factor beta 1-induced cell death in preneoplastic foci of rat liver and sensitization by the antiestrogen tamoxifen. Hepatology. 1996;23:840–847
  34. Tatsumura T, Sato H, Yamamoto K, Ueyama T. Ursodeoxycholic acid prevents gastrointestinal disorders caused by anticancer drugs. Jpn J Surg. 1981;11:84–89
  35. Riva C, Chauvin C, Pison C, Leverve X. Cellular physiology and molecular events in hypoxia-induced apoptosis. Anticancer Res. 1998;18:4729–4736

PII: S0306-9877(00)91071-5

doi: 10.1054/mehy.2000.1071

Medical Hypotheses
Volume 55, Issue 5 , Pages 379-382 , November 2000

Article Tools